Recent Studies Confirms: Rimonabant (Acomplia) Reduces Dangerous Abdominal Obesity
Recent studies with Cat (CT) scans of obese patients treated with Acomplia (rimonabant) have confirmed for the first time that the diet drug significantly reduces the dangerous type of abdominal obesity that often leads to type 2 diabetes, according to …